Recurrent IRTC invading the upper aerodigestive tract remains a formidable clinical challenge. Management typically involves tracheal resection or laryngectomy, often with sacrifice of the recurrent ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...

The genomic landscape of papillary thyroid cancer (PTC), the most common form of thyroid cancer, has just been redefined with respect to its somatic molecular alterations. In a new study published ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...